Covid-19: UK approves monoclonal antibody sotrovimab for over 12s at high risk
The UK’s medicines regulator has approved a second monoclonal antibody, sotrovimab, for the treatment of people over 12 years with mild to moderate covid-19 who are at high risk of developing severe…
